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AU : Pleaseconfirmthatallheadinglevelarerepresentedcorrectly:dherence t oral anticoagulant th r py in patients with atrial fibrillation (AF) in China is low.
Patient preference, one of the main reasons for discontinuation of oral anticoagulant ther-
apy, is an unfamiliar concept in China.
Methods and findings
A discrete choice experiment (DCE) was conducted to quantify patient preference on 7 attri-
butes of oral anticoagulant therapy: antidote (yes/no), food–drug interaction (yes/no), fre-
quency of blood monitoring (no need, every 6/3/1 month[s]), risk of nonfatal major bleeding
(0.7/3.1/5.5/7.8[%]), risk of nonfatal stroke (ischemic/hemorrhagic) or systemic embolism
(0.6/3.2/5.8/8.4[%]), risk of nonfatal acute myocardial infarction (AMI) (0.2/1.0/1.8/2.5[%]),
and monthly out-of-pocket cost (0/120/240/360 RMB) (0 to 56 USD). A total of 16 scenarios
were generated by using D-Efficient design and were randomly divided into 2 blocks. Eligible
patients were recruited and interviewed from outpatient and inpatient settings of 2 public
hospitals in Beijing and Shenzhen, respectively. Patients were presented with 8 scenarios
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Mixed logit regression model was used for estimating patients’ preferences of attributes of
oral anticoagulants and willingness to pay (WTP) with adjustments for age, sex, education
level, income level, city, self-evaluated health score, histories of cardiovascular disease/
other vascular disease/any stroke/any bleeding, and use of anticoagulant/antiplatelet ther-
apy. A total of 506 patients were recruited between May 2018 and December 2019 (mean
age 70.3 years, 42.1% women). Patients were mainly concerned about the risks of AMI (β:
−1.03; 95% CI: −1.31, −0.75; p < 0.001), stroke or systemic embolism (β: −0.81; 95% CI:
−0.90, −0.73; p < 0.001), and major bleeding (β: −0.69; 95% CI: −0.78, −0.60; p < 0.001)
and were willing to pay more, from up to 798 RMB to 536 RMB (124 to 83 USD) monthly.
The least concerning attribute was frequency of blood monitoring (β: −0.31; 95% CI: −0.39,
−0.24; p < 0.001). Patients had more concerns about food–drug interactions even exceed-
ing preferences on the 3 risks, if they had a history of stroke or bleeding (β: −2.47; 95% CI:
−3.92, −1.02; p < 0.001), recruited from Beijing (β: −1.82; 95% CI: −2.56, −1.07; p < 0.001),
or men (β: −0.96; 95% CI: −1.36, −0.56; p < 0.001). Patients with lower educational attain-
ment or lower income weighted all attributes lower, and their WTP for incremental efficacy
and safety was minimal. Since the patients were recruited from 2 major hospitals from devel-
oped cities in China, further studies with better representative samples would be needed.
Conclusions
Patients with AF in China were mainly concerned about the safety and effectiveness of oral
anticoagulant therapy. The preference weighting on food–drug interaction varied widely.
Patients with lower educational attainment or income levels and less experience of bleeding
or stroke had more reservations about paying for oral anticoagulant therapies with superior
efficacy, safety, and convenience of use.
Author summary
Why was this study done?
• Patient adherence with oral anticoagulant therapy in patients with atrial fibrillation
(AF) in China is poor. Patient preference on treatment attributes and their willingness
to pay (WTP) might be key factors in patient adherence.
• Results from studies using discrete choice experiment (DCE) outside China suggest that
preferences and WTP varied in different populations.
• Quantitative evaluation of patient preference on attributes of oral anticoagulants and
WTP in China remains an area that needs further exploration.
What did the researchers do and find?
• We conducted a survey using a DCE design to investigate preferences on attributes of
oral anticoagulants and WTP in patients with AF from Beijing and Shenzhen, 2 large
representative cities in China.
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Abbreviations: AU : Themainabbreviationlisthasbeenupdated:Pleaseverifythatallentriesarecorrect:F, atrial fibrillation; AMI, acute
myocardial infarction; CHA2DS2-VASc, congestive
heart failure (C), hypertension (H), age� 75 (A2),
diabetes mellitus (D), prior stroke or transient
ischemic attack or thromboembolism (S2),
vascular disease (V), age between 65 and 74 (A),
sex category (Sc); CI, confident interval; DCE,
discrete choice experiment; EHRA, European Heart
Rhythm Association; INR, international normalized
ratio; MI, myocardial infarction; mWTP, marginal
willingness to pay; NOAC, non-vitamin K antagonist
oral anticoagulant; RMB, Ren Min Bi (unit of
Chinese currency); SD, standard deviation; USD,
US dollar (unit of American currency); WTP,
willingness to pay.
• Patients were asked to choose their preferred treatment based on their evaluation of the
attributes of oral anticoagulant: antidote, food–drug interaction, frequency of blood
monitoring, risk of nonfatal major bleeding, risk of nonfatal stroke or systemic embo-
lism, risk of nonfatal acute myocardial infarction (AMI), and monthly out-of-pocket
cost.
• Patients were mostly concerned about the risks of AMI, stroke or systemic embolism,
and major bleeding and were willing to pay 798 to 536 RMB (124 to 83 USD) per month
to obtain a better drug with less risks. Food–drug interaction was weighted to be the
most important attribute by patients who had history of bleeding or stroke or who were
from Beijing.
What do these findings mean?
• The relatively highest preference weights for the risk of both cardiovascular and cere-
brovascular events indicate that patients might be more attentive to the safety of vital
organs than the main side effects of anticoagulant therapy.
• Patients with different demographic or health characteristics have specific preferences.
The relatively high preference weight and marginal willingness to pay (mWTP) for
food–drug interaction among specific patients suggest that patients might prefer the
most direct option offering rapid improvement.
Introduction
Oral anticoagulant therapy is a standard management for stroke prevention in patients with
atrial fibrillation (AF). In line with the increasing global prevalence of AF over the past decade
[1], the age- and sex-standardized prevalence of AF in Chinese over 35 year olds has continued
to rise, reaching 0.71% in 2017 [2]. Due to rapid action onset and offset, predictable pharmaco-
dynamics, and fewer food-drug interactions, non-vitamin K antagonist oral anticoagulants
(NOACs) are increasingly favored in clinical practice over warfarin worldwide [3] and has
been recommended in the latest international clinical practice guidelines [3–7]. However,
adherence to NOAC therapy among patients in China is lower than warfarin [8,9], although
the use of NOACs was found to be increasing rapidly [10].
One of the main reasons for discontinuation of NOACs is patient preference or affordabil-
ity [8]. A multicenter cross-sectional study found that out-of-pocket payment was the stron-
gest predictor for declining anticoagulant therapy use in China [11]. In China, although
NOACs have 92% of the oral anticoagulant therapy market share in terms of monetary value,
only 28% of patients with AF were prescribed a NOAC in 2017 [10]. Currently, for NOACs
prescribed in outpatient setting, only 70% of the cost will be subsidized [11]. Achieving a suffi-
cient reduction in the risk of ischemic stroke with an acceptable elevation in bleeding risk is an
important clinical trade-off that patients need to consider [12]. In addition, patients’ perspec-
tives concerning difficulties of access to the healthcare service and the complexity of treatment
will also influence medication adherence [13,14], a crucial issue for anticoagulant therapy as
emphasized in the 2018 European Heart Rhythm Association (EHRA) practical guide [6].
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However, current evidence is insufficient to rank the importance of factors affecting patients’
medication adherence in China.
Discrete choice experiment (DCE) is a method of eliciting and quantifying preferences and
exploring trade-offs between the attributes (characteristics) of alternatives [15]. An Australian
DCE study [12] indicated a consensus that patients were likely to choose more effective and
safer oral anticoagulant therapies and would prefer to pay more for a reduction in the risk of
stroke and bleeding. Although one United States study [16] supported this viewpoint, the
lower weight of these 2 attributes compared to blood testing and dietary restrictions height-
ened the concern for preference heterogeneity between different populations. This heterogene-
ity existed in the same country. Another US study [17] revealed that patients with
cardiovascular disease were not as concerned about the effectiveness and safety, including fatal
events, of oral anticoagulants as patients in the previous 2 studies.
Inconsistent results, as well as cultural differences between China and high-income coun-
tries, which could potentially impact the perspectives of patients receiving treatment, mean
that conclusions from previous studies conducted outside China may not be generalizable to
Chinese patients. To our knowledge, this is the first study to apply DCE to the investigation of
preferences on attributes of oral anticoagulant therapy and willingness to pay (WTP) among
patients with AF in China.
Methods
A cross-sectional questionnaire based on a face-to-face survey was conducted. Eligible patients
were recruited from both outpatient and inpatient settings of the cardiology departments of 2
public hospitals, the Chinese People’s Liberation Army General Hospital and The University
of Hong Kong—Shenzhen Hospital, located in 2 representative cities, Beijing and Shenzhen,
respectively. There was no prospective protocol published for this study.
Discrete choice experiment
Understanding the impact of the crucial attributes of treatments on patients’ decision-making
is more informative than merely understanding their preference of the actual product as a
whole. Attributes may have different weights that influence patients’ evaluation of the trade-
offs between treatments. Although traditional surveys can be used to obtain quantitative pref-
erences about products as a whole, it is difficult to compare the relative importance of these
individual attributes. DCE is a mature method to easily measure the level of risk/benefit that
patients would take/give up for one attribute in exchange for the benefit of another. By using
this approach, we may be able to ascertain the dominating factors that influence patients when
choosing treatments, as well as the price they are prepared to spend to be free of or obtain spe-
cific attributes. Therefore, the results could assist clinicians, pharmaceutical companies, gov-
ernments, and other stakeholders in adjusting treatment plan, improving products, and
offering more reasonable pricing, which could improve medication adherence. This study
used a DCE design to quantitatively assess patients’ preferences of the most important attri-
butes for oral anticoagulants. The entire experiment adhered to the recommendations of the
International Society for Pharmacoeconomics and Outcome Research protocol for conducting
DCE [18].
Target population and sample size
A convenience sampling approach was used to recruit patients who were (i) diagnosed with
AF; (ii) aged�18 years old; (iii) with congestive heart failure (C), hypertension (H), age� 75
(A2), diabetes mellitus (D), prior stroke or transient ischemic attack or thromboembolism (S2),
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vascular disease (V), age between 65 and 74 (A), sex category (Sc) (CHA2DS2-VASc)�1 for
men and CHA2DS2-VASc�2 for women; and (iv) without communication impediments.
Attribute and level identification
A total of 7 attributes of oral anticoagulants (Table 1) were identified based on the evidence
from previous studies [12,16,17,19–21], in addition to the ranking by an expert panel with 40
cardiologists and 40 eligible patients. Two levels were assigned to the attributes of antidote and
food–drug interaction. Patients who use warfarin drugs are subject to monthly blood monitor-
ing although this is not necessary for NOAC users. We used 4 levels, every 1/3/6 month(s) or
not required/necessary, for this attribute in order to determine the preferred monitoring fre-
quency for clinical application. Four levels were used for the risk of nonfatal major bleeding
(0.7/3.1/5.5/7.8[%]), the risk of nonfatal stroke or systemic embolism (0.6/3.2/5.8/8.4[%]), and
the risk of nonfatal acute myocardial infarction (AMI) (0.2/1.0/1.8/2.5[%]) [22–27]. The high-
est and lowest rates of the aforementioned 3 risk events when using oral anticoagulants
Table 1. Selected attributes of oral anticoagulants.
Attributes� Levels
Antidote could be provided if there was a side effect when administrating oral anticoagulant Yes/no
Food–drug interaction exists when administrating oral anticoagulant Yes/no





Probability that you would encounter a nonfatal major bleeding event when administrating
oral anticoagulant
0.7/3.1/5.5/7.8 (%)
Probability that you would encounter a nonfatal stroke (either ischemic or hemorrhagic) or
systemic embolism event when administrating oral anticoagulant
0.6/3.2/5.8/8.4 (%)
Probability that you would encounter a nonfatal AMI event when administrating oral
anticoagulant
0.2/1.0/1.8/2.5 (%)
Out-of-pocket monthly cost 0/120/240/360
(RMB)#
�Bleeding is the main side effect for stroke prevention in the treatment using oral anticoagulants among patients with
AF. Attributes of oral anticoagulants valued by patients the most would logically be the risks of bleeding and stroke,
which represent the safety and effectiveness of drugs. Some characteristics, which are not direct attributes of oral
anticoagulants such as risk of MI, may still concerned by patients in China. In addition, any attributes that are crucial
and vary between different oral anticoagulants may also influence patients’ choice of anticoagulation therapy.
Risks of bleeding, stroke, and MI were expanded into different levels based on the severity. They were fatal bleeding
risk, nonfatal major bleeding risk, nonfatal minor bleeding risk, nonfatal any bleeding risk, fatal stroke or MI risk,
nonfatal major stroke risk, nonfatal minor stroke risk, nonfatal any stroke risk, and nonfatal MI risk. Besides,
antidote, blood test requirement, food–drug interaction, dose adjustment, frequency of drug administration, as well
as out-of-pocket cost, which is always the key attribute for mWTP calculation, were ranked by 40 cardiologists and
40 eligible patients.
Risks of bleeding, stroke, and MI were the most concerned attributes of oral anticoagulant for both patients and
clinicians. In order to avoid potential bias induced by fatal risks, which dominated patients’ decision in our
exploratory experiment, fatal risks were removed. As patients had difficulties in distinguishing ischemic stroke and
hemorrhagic stroke in our exploratory experiment, stroke were described as ischemic or hemorrhagic.
#1 USD� 6.4 RMB.
RMB indicates Ren Min Bi, the unit of Chinese currency.
AAU : AbbreviationlistshavebeencompiledforthoseusedthroughoutTables1   4:Pleaseverifythatallentriesarecorrect:F, atrial fibrillation; AMI, acute myo ardial infarc ion; MI, myocardial infarction; mWT , marginal willingness o
pay.
https://doi.org/10.1371/journal.pmed.1003730.t001
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reported from observational studies were used as the ceiling and baseline levels of attributes,
respectively, with the ranges equally divided into 4. The monthly out-of-pocket cost of NOAC
for a patient with medical insurance is approximately 150 to 300 RMB (23 to 47 USD). As
most patients would have medical insurance, the levels for this attribute were expressed as 0/
120/240/360 RMB.
DCE design
To prevent an impractically large sample size reaching sufficient power, we used a D-Efficient
design to generate a set of choices consisting of 16 combinations from a full factorial design,
which had 2 × 2 × 4 × 4 × 4 × 4 × 4 = 4,096 hypothetical profiles for each alternative in this
study. In order to give a manageable workload to each patient while harnessing the statistical
properties, 16 scenarios with different combinations of hypothetical profiles of alternatives
were randomly divided into 2 blocks, with each block including 8 scenarios. Eligible patients
were randomly allocated to one of the 2 blocks.
The names of alternatives could distract patients’ attention from the targeting attributes
and bias their preferences, especially when the population has a different understanding about
the products [28,29]. Therefore, patients were asked to choose one preferred oral anticoagulant
from 2 unlabeled hypothetical treatments. One “opt-out” option (i.e., no anticoagulant ther-
apy) would be chosen if patients disliked either treatments based on the provided attribute lev-
els. This could provide a more realistic preference [30].
A testing scenario with a dominated alternative was included at the beginning to assess
patients’ understanding (S1 File). Investigators would immediately explain the meaning of levels
of attributes to those who did not choose the dominated alternative. Those patients were allowed
to continue answering the questionnaire only when their understanding were confirmed by
investigators. DCEs were generated by Ngene V1.1.2 (CAU : PleaseprovidethemanufacturerlocationforChoiceMetricsinthesentenceDCEsweregeneratedby::::hoiceM tricsAU : PleasenotethatPLOSdoesn tallowInc:; Ltd:; e c:; inthemanuscriptexceptas ppropriateintheaffiliations:, W201/599 Pacifi
Highway, St Leonards, Sydney, NSW 2065, AU) (S2 and S3 Files).
Sample size
According to Orme’s rule of thumb formula, minimum sample size =
500�ðlargest level of attributesÞ
ðnumber of scenariosÞ�ðnumber of non opt  out alternativesÞ [31]. Given the conditions of 2 alternatives (excluding
opt-out), and maximum 4 levels for attributes, as well as 8 scenarios presented to each patient
to obtain the largest minimum required sample size, at least 125 participants in total are
required. To ensure sufficient power, we aimed to recruit 300 patients for each site [31].
Data collection
Eligible patients identified between May 2018 and December 2019 by cardiologists were trans-
ferred to trained investigators for the subsequent investigation. The purpose of this study,
basic information about oral anticoagulant therapy, and how to complete the DCE question-
naire were explained by the site investigator. All patients who signed the consent forms were
included in the analyses. Face-to-face interviews were conducted via paper-based question-
naires (S4 File). Patient demographic characteristics, such as age, sex, occupation, education
level, monthly income after tax, medical insurance type, history of cardiovascular medication,
history of diseases, self-evaluated health score, were also collected for analyses (Table 2).
Analyses
Mixed logit regression model was used for the main analysis to estimate patients’ preferences
on each attribute. CAU : PleasecheckwhethertheeditstothesentenceConsideringtheassumptionofindependence:::arecorrect; andprovidecorrectwordingifnecessary:onsidering the assumption of independe c for outcomes in mixed log t
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Table 2. Characteristics of recruited patients.
Characteristics Total (n = 506) Beijing (n = 299) Shenzhen (n = 207)�
Number of patients who failed in the testing scenario# 36 (7.1) 20 (6.7) 16 (7.7)
Sociodemographic profile
Age, mean (SD), y 70.3 (12.7) 70.8 (13.2) 69.5 (12.0)
Women 213 (42.1) 99 (33.1) 114 (55.1)
Inpatient setting 366 (72.3) 201 (67.2) 165 (79.7)
Education
Illiteracy 19 (3.8) 2 (0.7) 17 (8.2)
Primary school 71 (14.0) 36 (12.0) 35 (16.9)
Secondary school 197 (38.9) 107 (35.8) 90 (43.5)
Undergraduate 193 (38.1) 134 (44.8) 59 (28.5)
Postgraduate 26 (5.1) 20 (6.7) 6 (2.9)
Occupation
Full-time job 74 (14.6) 48 (16.1) 26 (12.6)
Part-time job 1 (0.2) 0 (0) 1 (0.5)
Student 0 (0) 0 (0) 0 (0)
Peasant 53 (10.5) 39 (13.0) 14 (6.8)
Housewife 28 (5.5) 17 (5.7) 11 (5.3)
Retired 344 (68.0) 195 (65.2) 149 (72.0)
Unemployed 6 (1.2) 0 (0) 6 (2.9)
Individual monthly income after tax (RMB)
�5,000 215 (42.5) 91 (30.4) 124 (60.0)
5,001–12,000 277 (54.7) 201 (67.2) 76 (36.7)
>12,000 14 (2.8) 7 (2.3) 7 (3.4)
Medical condition
Self-evaluated health score, mean (SD) 62.4 (17.4) 60.2 (16.9) 65.7 (17.5)
Self-reported histories of diseases
Cardiovascular disease 391 (77.3) 220 (73.6) 171 (82.6)
Other vascular disease 235 (46.4) 195 (65.2) 40 (19.3)
Stroke/transient ischemic attack/systemic embolism 117 (23.1) 88 (29.4) 29 (14.0)
Renal impairment 70 (13.8) 36 (12.0) 34 (16.4)
Bleeding (major/minor) 53 (10.5) 38 (12.7) 15 (7.2)
Liver impairment 20 (4.0) 17 (5.7) 3 (1.4)
Other thrombosis 11 (2.2) 11 (3.7) 0 (0)
Self-reported histories of medication use
Anticoagulant 394 (77.9) 214 (71.6) 180 (87.0)
Antiarrhythmic agent 318 (62.8) 148 (49.5) 170 (82.1)
Lipid-lowering agent 311 (61.5) 177 (59.2) 134 (64.7)
Antihypertensive agent 319 (63.0) 183 (61.2) 136 (65.7)
Antihyperglycemic agent 117 (23.1) 65 (21.7) 52 (25.1)
Antianginal agent 104 (20.6) 93 (31.1) 11 (5.3)
Antiplatelet agent 95 (18.8) 62 (20.7) 33 (15.9)
Type of medical insurance&
Employee insurance 171 (33.8) 97 (32.4) 74 (35.7)
Resident insurance 90 (17.8) 7 (2.3) 83 (40.1)
Military medical service 63 (12.5) 62 (20.7) 1 (0.5)
Rural insurance 60 (11.9) 38 (12.7) 22 (10.6)
Free medical service 44 (8.7) 40 (13.4) 4 (1.9)
(Continued)
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regression model would have been violated because the selection of “opt-out” option would be
highly dependent on the selection of “drug A” and “drug B”, scenarios with opt-out selected
were removed from the main analysis. Antidote and food–drug interaction were treated as
binary; the frequency of blood monitoring was treated as ordinal; all of the risk attributes and
the monthly out-of-pocket cost were treated as continuous variables. Factors that could influ-
ence patients’ understandings for questionnaire, such as education level, income level, and
city, were adjusted. Factors that could represent patients’ previous experiences on anticoagu-
lant therapy, such as self-evaluated health score, histories of cardiovascular disease/other vas-
cular disease/any stroke/any bleeding, and use of anticoagulant/antiplatelet, were adjusted. As
common confounders, age and sex were also adjusted. Random effects for each attribute were
taken into consideration to minimize the effects from residual confounders that induced het-
erogeneity in patients, except for out-of-pocket cost, which was treated as a fixed effect to cal-
culate WTP. The correlation between any pair of attributes was also adjusted in the model.
McFadden Pseudo R2 was used to evaluate the goodness of fit for models [32]. Marginal will-
ingness to pay (mWTP) was calculated by assessing the ratio of the preference of other attri-
butes to the preference of out-of-pocket cost (Table 3). Subgroup analyses by sex, education
level (under or above high school), income level (under or above 5,000 RMB [775 USD] per
month), with or without history of any stroke/bleeding, and cities were performed (Table 4).
Several sensitivity analyses were performed to test the robustness of our results. Firstly,
patients who failed the testing scenario were removed from the analysis to assess the quality of
our data (S5 File). Furthermore, to determine more specific preferences, the frequency of
blood monitoring was treated as a categorical variable (S6 File). Block of scenarios was
adjusted in mixed logit regression model to assess the potential impact of blocks on prefer-
ences (S7 File). An analysis stratified by outpatient and inpatient setting was conducted to
assess the potential influence from different settings (S8 File). As medical insurance may influ-
ence patients’ preferences, an analysis with the exclusion of all patients who did not have any
medical insurance was performed (S9 File). Two additional statistical models, nested logit
model and multinomial logit model, were used to assess the influence of the opt-out option
(S10 and S11 Files).
Table 2. (Continued)
Characteristics Total (n = 506) Beijing (n = 299) Shenzhen (n = 207)�
Retirement insurance 34 (6.7) 26 (8.7) 8 (3.9)
Commercial insurance 14 (2.8) 11 (3.7) 3 (1.4)
None 28 (5.5) 21 (7.0) 7 (3.4)
�Patients recruitment in Shenzhen site was terminated due to the COVID-19 pandemic in early 2020.
#A testing scenario (S1 File) was designed to test whether patients understood the DCE questionnaire. In this scenario, drug A is obviously worse than drug B, because
drug A has higher risks of suffering from side effect, including bleeding, MI, has higher risk of suffering from stroke, has food–drug interaction but no antidote, and has
a higher price. If patients did not choose drug B, it indicated they might not understand this questionnaire. Investigators would immediately explain the meaning of
levels of attributes to them. These patients were allowed to answer the questionnaire only when their understandings were confirmed by investigators. After
investigators’ explanation, these patients were considered to have similar understanding to other patients and were included in analyses.
&AU : PleasenotethatthefootnotedesignatorisnotcitedinbodyofTable2:Pleasecheckandprovidethemissingdesignator:Employee insurance indicates mandatory insurance for those who are in employment; resident insurance indicates mandatory insurance for those living in the city.
Military medical service indicates free medical services for those who are working or were previously in the army; rural insurance indicates insurance for people who
living in rural areas; free medical services are for those meet specific criteria; retirement insurance applies to those already retired; and commercial insurance is
applicable to all.
RMB indicates Ren Min Bi, the unit of Chinese currency.
COVID-19, Coronavirus Disease 2019; DCE, discrete choice experiment; MI, myocardial infarction.
https://doi.org/10.1371/journal.pmed.1003730.t002
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The main analysis, subgroup analyses, and sensitivity analyses (to test the robustness of dif-
ferent models) were prespecified, conducted, and reported as planned (S10 and S11 Files).
Additional sensitivity analyses (S5–S9 Files) that had been added to test the robustness of the
results against the main results were data driven. All statistical analyses were conducted using
R 3.6.3 (R Core Team 2020, Austria). Patient characteristics were summarized as mean (SD)
for continuous variables and in frequencies (percentage) for categorical variables. All hypothe-
sis tests were 2 sided, with a significance level of 0.05. This study was approved by the ethics
committees of both Chinese People’s Liberation Army General Hospital and The University of
Hong Kong-Shenzhen Hospital.
Results
Characteristics of patients (Table 2)
After excluding one patient who did not answer any question, a total of 506 patients (299 from
Beijing and 207 from Shenzhen), with mean age 70.3 years, of which 42.1% were women, were
successfully recruited and completed consent forms. Regardless of testing scenario, each
patient was given 8 scenarios with 2 treatment alternatives and one opt-out option to choose
from, and a result of 12,144 (506 × 8 × 3) completed records were expected. After removing
201 empty responses, 11,943 records were kept for further analyses. The first and second
blocks were answered by 254 and 252 patients, respectively (S4 File). A total of 36 out of 506
patients (7.1%) did not choose the dominant drug in the testing scenario.
Main analysis (Table 3)
The positive and negative values of coefficients represent patients’ preference and dislike for
the corresponding attribute, respectively. The greater the absolute value of the coefficient, the
more weight for changes per unit of that attribute were taken into consideration when patients
evaluated the trade-offs.
Table 3. Preference weights estimated by mixed logit regression model and mWTP (RMB�) in main analysis.
Attribute Crude estimation Adjusted estimation# mWTP (95% CI)
β (95% CI) p-Value& β (95% CI) p-Value&
Out-of-pocket monthly cost −0.0011 (−0.0014, −0.0008) <0.001 −0.0013 (−0.0016, −0.0009) <0.001 -
Risk of nonfatal AMI −0.85 (−1.08, −0.62) <0.001 −1.03 (−1.31, −0.75) <0.001 −798 (−1,247, −518)
Risk of nonfatal stroke or systemic embolism −0.70 (−0.76, −0.64) <0.001 −0.81 (−0.90, −0.73) <0.001 −632 (−880, −488)
Risk of nonfatal major bleeding −0.58 (−0.65, −0.52) <0.001 −0.69 (−0.78, −0.60) <0.001 −536 (−762, −403)
Food–drug interaction −0.36 (−0.55, −0.16) <0.001 −0.63 (−0.88, −0.38) <0.001 −489 (−764, −288)
Antidote 0.45 (0.22, 0.68) <0.001 0.43 (0.17, 0.69) 0.001 338 (125, 639)
Frequency of blood monitoring −0.28 (−0.34, −0.22) <0.001 −0.31 (−0.39, −0.24) <0.001 −244 (−347, −180)
Model specifications Crude: Log likelihood = −2,081; McFadden Pseudo R2 = 0.1898
Adjusted: Log likelihood = −2,030; McFadden Pseudo R2 = 0.2096
�1 USD� 6.4 RMB.
#Adjusted by age, sex, education level, income level, city, self-evaluated health score, history of cardiovascular disease/other vascular disease/any stroke/any bleeding,
and use of anticoagulant/antiplatelet; the correlation between any pair of attributes was also involved in the model.
&p-Values for coefficients were obtained by Wald test.
mWTP indicates marginal willingness to pay; it was calculated under adjusted estimations. Krinsky and Robb’s method was used to calculate 95% CI of mWTP. RMB
indicates Ren Min Bi, the unit of Chinese currency. β indicates coefficient and represents relative weight; negative value indicates negative preference.
AMI, acute myocardial infarction.
https://doi.org/10.1371/journal.pmed.1003730.t003
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Table 4. Preference weights estimated by mixed logit regression model and mWTP (RMB�) in subgroup analyses.
Stratified by sex
Attribute Men (n = 293) Women (n = 213)
Crude estimation Adjusted estimation# mWTP
(95% CI)
Crude estimation Adjusted estimation# mWTP (95%
CI)β (95% CI) p-
Value&
β (95% CI) p-
Value&
β (95% CI) p-
Value&


































































































Model specification Men (crude model): Log likelihood = −1,160; McFadden Pseudo R2 = 0.2114
Men (adjusted model): Log likelihood = −1,114; McFadden Pseudo R2 = 0.2424
Women (crude model): Log likelihood = −903; McFadden Pseudo R2 = 0.1771
Women (adjusted model): Log likelihood = −873; McFadden Pseudo R2 = 0.2051
Stratified by education level
Attribute At or under high school (n = 287) Over high school (n = 219)
Crude estimation Adjusted estimation# mWTP
(95% CI)
Crude estimation Adjusted estimation# mWTP (95%
CI)β (95% CI) p-
Value&
β (95% CI) p-
Value&
β (95% CI) p-
Value&
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Table 4. (Continued)
Model specification At or under high school (crude model): Log likelihood = −1,201; McFadden Pseudo R2 = 0.1902
At or under high school (adjusted model): Log likelihood = −1,168; McFadden Pseudo R2 = 0.2128
Over high school (crude model): Log likelihood = −792; McFadden Pseudo R2 = 0.2695
Over high school (adjusted model): Log likelihood = −764; McFadden Pseudo R2 = 0.2956
Stratified by income level§
Attribute �5,000 RMB monthly income (n = 215) >5,000 RMB monthly income (n = 291)
Crude estimation Adjusted estimation# mWTP
(95% CI)
Crude estimation Adjusted estimation# mWTP (95%
CI)β (95% CI) p-
Value&
β (95% CI) p-
Value&
β (95% CI) p-
Value&




































































































Model specification �5,000 RMB monthly income (crude model): Log likelihood = −927; McFadden Pseudo R2 = 0.1632
�5,000 RMB monthly income (adjusted model): Log likelihood = −896; McFadden Pseudo R2 = 0.1915
>5,000 RMB monthly income (crude model): Log likelihood = −1,061; McFadden Pseudo R2 = 0.2736
>5,000 RMB monthly income (adjusted model): Log likelihood = −1,022; McFadden Pseudo R2 = 0.2998
Stratified by history of bleeding or stroke
Attribute Without history of bleeding or stroke (n = 354) With history of bleeding or stroke (n = 152)
Crude estimation Adjusted estimation# mWTP
(95% CI)
Crude estimation Adjusted estimation# mWTP (95%
CI)β (95% CI) p-
Value&
β (95% CI) p-
Value&
β (95% CI) p-
Value&
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Compared to other attributes, the relatively higher weights for the risk of nonfatal AMI
(β: −1.03; 95% CI: −1.31, −0.75; p< 0.001), the risk of nonfatal stroke or systemic embolism
(β: −0.81; 95% CI: −0.90, −0.73; p< 0.001), and the risk of nonfatal major bleeding (β: −0.69;
95% CI: −0.78, −0.60; p< 0.001) indicate that the issues patients had the most concern about
during anticoagulant therapy were safety and effectiveness. The impact of the frequency of
blood monitoring on decision-making was the weakest (β: −0.31; 95% CI: −0.39, −0.24;
p< 0.001), and patients disliked frequent hospital visits. Patients preferred treatment with the
antidote (β: 0.43; 95% CI: 0.17, 0.69; p = 0.001), while avoiding food–drug interactions (β:
−0.63; 95% CI: −0.88, −0.38; p< 0.001).
Patients were willing to pay most of the cost for oral anticoagulant therapy: 798 RMB (β:
−798; 95% CI: −1,247, −518), 632 RMB (β: −632; 95% CI: −880, −488), and 536 RMB (β: −532;
95% CI: −762, −403), respectively, to reduce 1% of the risk of nonfatal AMI, nonfatal stroke or
systemic embolism, and nonfatal major bleeding. They began to hesitate about paying more to
Table 4. (Continued)
Model specification Without history of bleeding or stroke (crude model): Log likelihood = −2,010; McFadden Pseudo R2 = 0.1869
Without history of bleeding or stroke (adjusted model): Log likelihood = −1,446; McFadden Pseudo R2 = 0.1879
With history of bleeding or stroke (crude model): Log likelihood = −542; McFadden Pseudo R2 = 0.3120
With history of bleeding or stroke (adjusted model): Log likelihood = −510; McFadden Pseudo R2 = 0.3521
Stratified by city
Attribute Beijing (n = 299) Shenzhen (n = 207)
Crude estimation Adjusted estimation# mWTP
(95% CI)
Crude estimation Adjusted estimation# mWTP (95%
CI)β (95% CI) p-
Value&
β (95% CI) p-
Value&
β (95% CI) p-
Value&































































































Model specification Beijing (crude model): Log likelihood = −1,119; McFadden Pseudo R2 = 0.2721
Beijing (adjusted model): Log likelihood = −1,044; McFadden Pseudo R2 = 0.3210
Shenzhen (crude model): Log likelihood = −869; McFadden Pseudo R2 = 0.1562
Shenzhen (adjusted model): Log likelihood = −833; McFadden Pseudo R2 = 0.1917
�1 USD� 6.4 RMB.
#Adjusted by age, sex, education level, income level, city, self-evaluated health score, history of cardiovascular disease/other vascular disease/any stroke/any bleeding,
and use of anticoagulant/antiplatelet; the correlation between any pair of attributes was also involved in the model.
&p-Values for coefficients were obtained by Wald test.
§Using 5,000 RMB as an individual monthly income cutoff point as this is the current threshold for personal income tax payment in China.
mWTP indicates marginal willingness to pay; it was calculated under adjusted estimations. Krinsky and Robb’s method was used to calculate 95% CI of mWTP. RMB
indicates Ren Min Bi, the unit of Chinese currency. β indicates coefficient and represents relative weight; negative value indicates negative preference.
AMI, acute myocardial infarction.
https://doi.org/10.1371/journal.pmed.1003730.t004
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be free of food–drug interaction (β: −489; 95% CI: −764, −288) or to obtain the extra antidote
for side effects and reactions (β: 338; 95% CI: 125, 639) and were willing to pay only the mini-
mum to reduce the frequency of blood monitoring (β: −244; 95% CI: −347, −180).
Subgroup analyses (Table 4)
Men were slightly more concerned about almost all of the attributes compared to women and
were willing to pay double that of women. The impact of food–drug interaction on men (β:
−0.96; 95% CI: −1.36, −0.56; p< 0.001) was much stronger than that on women (β: −0.34; 95%
CI: −0.73, 0.05; p = 0.09), and they were willing to pay over 4 times more than women (805 ver-
sus 174 RMB [125 versus 27 USD]).
As is widely known, education level correlates with income level. The similarity in patterns
of preferences on all attributes could also be observed for both subgroups; patients with lower
educational attainment (at or under high school) or who had a lower income (�5,000 RMB/
month) were less concerned about all of the attributes and were only willing to pay the mini-
mum to obtain extra benefits or get rid of disadvantages. mWTP varied widely among patients
with higher levels of education and income.
History of any bleeding or stroke influenced patients’ preference. Anyone with a history
valued all attributes at the same high weights and were willing to pay up to 5 times of those
without a history. For this group, food–drug interaction was the most concerning attribute (β:
−2.47; 95% CI: −3.92, −1.02; p< 0.001).
We stratified the analysis by cities to test heterogeneity. Compared to Shenzhen, the effect
size of all attributes on patients from Beijing was chiefly doubled. The food–drug interaction
had the strongest impact on patients from Beijing (β: −1.82; 95% CI: −2.56, −1.07; p< 0.001).
However, they were only willing to pay less than the amount that patients from Shenzhen were
prepared to pay for most of the attributes.
Sensitivity analyses (S5–S11 Files)
First, we removed patients who did not initially select the dominated alternative in the testing
scenario to assess data quality. Preferences and mWTP for each attribute were consistent with
the primary analysis (S5 File).
With consideration that the linear assumption might be violated in the ordinal variable fre-
quency of blood monitoring since the intervals between each level were unequal, we also treated
this as a categorical variable (S6 File). Compared to nonnecessity for monitoring, patients pre-
ferred less frequent 6 monthly hospital visits (β: 0.43; 95% CI: 0.18, 0.69; p< 0.001). The extent
of dislike deteriorated as the frequency increased (every 3 months β: −0.30; 95% CI: −0.54,
−0.05; p = 0.02 and every 1 month β: −0.85; 95% CI: −1.09, −0.61; p< 0.001).
The consistent results of the sensitivity analyses, which adjusted blocks of scenarios, strati-
fied by outpatient and inpatient settings, and excluded patients who did not have any medical
insurance, from main analysis, indicated that there would not be obvious influence from those
aforementioned factors on patients’ preferences (S7–S9 Files).
By adopting a nested logit model to assess the effects of opt-out on decision-making, the
preferences for all attributes were principally similar to that in the main analysis. However,
due to the inability to deal with the correlated alternative selection, the results from multino-
mial logistic regression were not consistent with the main analysis (S10 and S11 Files).
Discussion
In view of the underutilization of oral anticoagulant therapy and poor medication adherence
among patients with AF in China, this study provides an in-depth exploration of the crucial
PLOS MEDICINE Preference and WTP on oral anticoagulant of patients with AF in China
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003730 August 26, 2021 13 / 19
factors that could affect patients’ preferences, allowing either possible product improvements
or therapeutic focused adjustments. In addition, as apixaban and edoxaban have not yet been
approved for use in China, the results from mWTP could assist with reasonable pricing for the
remaining NOACs in China.
The magnitude of concerns about the attributes vary in different populations. In general,
the risks of AMI, stroke or systemic embolism, and major bleeding, which could intuitively
reflect drug safety and effectiveness, emerged as characteristics for which patients were willing
to pay most for improvement. The relatively higher preference weights for the risk of both car-
diovascular and cerebrovascular events indicate that patients might be more attentive to the
safety of vital organs than the common severe side effects during anticoagulant therapy. Dis-
ease conditions of the heart or brain necessitate inevitable long-term medical care, which place
a heavy burden on most families in China. This finding is consistent with another US study
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which suggested that Chinese patients might have different perspectives about the attributes
compared to patients from high-income countries. A recent study found that the general spa-
tial accessibility to hierarchical healthcare facilities in Shenzhen is unevenly distributed and
concentrated [33]. Also, the supply of healthcare resources at primary care facilities is far from
sufficient. This might reveal the reason why patients in our study were more concerned about
blood monitoring. More frequent blood test monitoring is inconvenient for many patients
who do not reside near their primary healthcare facility. Another study focused on oral antic-
oagulation adherence of patients in China suggested that consecutive international normalized
ratio (INRAU : PleasenotethatINRhasbeendefinedasinternationalnormalizedratiointhesentenceAnotherstudyfocusedonoralanticoagulation::::Pleasecheckandcorrectifnecessary:) monitoring was major concern of patie s, especi lly for those wh are older,
women, and have previous stroke history, as they are at a higher risk of bleeding and need
more intensive INR monitoring [34].
Patients with different demographic or health characteristics have their specific preferences.
The most surprising finding was that the preference weight of food–drug interaction was the
highest among men, patients who had been recruited from Beijing, and who had a history of
bleeding or stroke. The dietary habits of Chinese is complex. Green vegetables, rich in vitamin
K, which could influence the effectiveness of vitamin K antagonist oral anticoagulants, are usu-
ally a main dietary preference. Drinking alcohol is also taboo while under drug treatment.
However, one of the main social activities in China is attending banquets, especially common
among northern residents and men. This might be the reason that the preference weight
among these patients was high. Patients with history of bleeding or stroke who were concerned
mainly with food–drug interactions could have experienced severe adverse reactions caused by
poor dietary habits. In addition, the relatively high mWTP for this attribute suggest that
patients might prefer the most direct option offering rapid improvement.
Currently, patients with AF in China are generally required to pay an additional 150 to 300
RMB per month for anticoagulant therapy using NOAC. According to our results, patients
were willing to pay a little more than the current monthly expenditure for oral anticoagulants
with better safety, effectiveness, and convenience profiles. Nevertheless, if the drug attribute
preferences of patients with low income were the same as that of the overall population, their
WTP would be understandably low. It is worth noting that the preferences of patients with
high income and high educational attainment varied widely. The insignificance of out-of-
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pocket costs suggests that current incremental cost was within the affordable range for this
population.
Limitations
There were several limitations in this study. First, as discussed in other stated preference sur-
veys, the true preferences were not revealed because the decisions made were merely hypothet-
ical. Second, all scenarios only considered a limited number of attributes. Other attributes,
such as the risk of bleeding with different severity levels and side effect related death, for exam-
ple, may also reflect other preferences. Nevertheless, those 7 included attributes were the one
mostly concerned by patients in other DCE studies. Regardless of sample size increase, too
many attributes would also increase patient workload, affecting their decision-making due to
information overload and reduce the reliability of the result. Some attributes, such as death,
could be a distraction and bias the result. Third, we cannot fully ascertain whether patients
prefer NOACs or warfarin due to the unlabeled design. However, patients might be biased by
the names of alternatives without an understanding of the products. Moreover, the unlabeled
approach may help identify patients’ preferences more accurately. Forth, due to the nature of
DCE, there may not be a flawless analytic approach to obtain a comprehensive result. How-
ever, we have conducted several sensitivity analyses using different models with consistent
results. Fifth, the levels of risks of major bleeding, stroke and systemic embolism, and myocar-
dial infarction were obtained from studies mainly on non-Chinese/Asian populations. The
estimated preferences on these attributes might be less generalizable to a Chinese population.
However, the findings may not be too biased due to the linear assumption, as long as the differ-
ences of those risks between the 2 populations are not large and are still useful especially for
the firsthand evidence from an exploratory study. Lastly, the 2 hospitals that were used to
recruit patients are the major hospitals in 2 developed and affluent cities in China. Patients
from these 2 hospitals may not be representative of patients in China in general.
Conclusions
Patients with AF in China were mainly concerned with the safety and effectiveness of oral anti-
coagulant therapy. The preference weight on food–drug interaction varied widely. Patients
with lower educational attainment or low income and less experience of bleeding or stroke
were more conservative about paying for oral anticoagulant therapies with superior efficacy,
safety, and convenience of use.
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